ADA | Jotup

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

Retrieved on:

星期五, 五月 31, 2024

Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Arrowhead, American Diabetes Association, EASL, Therapy, DSM-IV codes, APCN, Conference, Congress, EGS

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points:

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
16th European Glaucoma Society (EGS) Congress – June 1-4, 2024
Jefferies Global Healthcare Conference – June 5-6, 2024
European Association for the Study of the Liver (EASL) Congress 2024 – June 5-8, 2024
Goldman Sachs 45th Annual Global Healthcare Conference – June 10-13, 2024
22nd Asian Pacific Congress of Nephrology (APCN 2024) – June 13-16, 2024
American Diabetes Association (ADA) 84th Scientific Sessions – June 21-24, 2024
Title: Liver-specific silencing of INHBE with ARO-INHBE, an siRNA therapeutic, for metabolic diseases
6th Annual RNA Therapeutics Conference | Symposium 2024 From Concept to Clinic – June 26-28, 2024
Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions

Retrieved on:

星期三, 五月 29, 2024

Patient, Obesity, American Diabetes Association, Glycemia, T2D, KOL, Body composition, Therapy, Entrepreneurship, Music

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that it will present new preclinical obesity data from its pancreatic gene therapy platform, Rejuva, at the upcoming American Diabetes Association (ADA)’s 84th Scientific Sessions taking place June 21-24, 2024 in Orlando, FL.

Key Points:

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that it will present new preclinical obesity data from its pancreatic gene therapy platform, Rejuva, at the upcoming American Diabetes Association (ADA)’s 84th Scientific Sessions taking place June 21-24, 2024 in Orlando, FL.
Presenter: Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer, Fractyl Health
Fractyl Health will host an in-person Key Opinion Leader (KOL) event during the ADA’s 84th Scientific Sessions.
The event will take place on Monday, June 24, 2024, from 7:00 a.m. – 8:00 a.m.
In addition, members of Fractyl management will discuss the Company’s two novel platforms, Revita® and Rejuva, and their potential to be a single-administration disease-modifying solution.

Generational Group Advises DTX Media in its Sale to DevRight

Retrieved on:

星期三, 五月 29, 2024

Generational Group , a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of its client DTX Media, LLC to DevRight, LLC.

Key Points:

Generational Group , a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of its client DTX Media, LLC to DevRight, LLC.
DTX Media (DTX), headquartered in Dallas, Texas, is a corporate video production company.
Located in Dallas, Texas, DevRight provides support, education, and other developmental services to professionals in a variety of industries.
DevRight could not have found a better company than DTX to complete their host of services.

Ada Enhances AI Agent for Customer Service on the Path to Enable 100% Automated Resolution Rate

Retrieved on:

星期四, 五月 23, 2024

Today Ada , the AI-native customer service automation company, announced a series of AI management and coaching capabilities that upskill its AI Agent and set businesses on the path towards 100% automated resolution rate.

Key Points:

Today Ada , the AI-native customer service automation company, announced a series of AI management and coaching capabilities that upskill its AI Agent and set businesses on the path towards 100% automated resolution rate.
Having powered more than 4 billion automated customer interactions since 2016, Ada launched its AI Agent for customer service, powered by the Ada Reasoning Engine™, in November 2023.
It doesn’t stop there – Ada’s new AI coaching and management tools will upskill its AI Agent to deliver even more extraordinary customer experiences.
We’ve made onboarding, measuring and coaching the AI Agent for customer service as familiar and intuitive as managing a human.

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Retrieved on:

星期三, 五月 22, 2024

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial ( NCT06380907 ) evaluating the efficacy and safety of the company’s internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis (CPP).

Key Points:

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial ( NCT06380907 ) evaluating the efficacy and safety of the company’s internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis (CPP).
Emphasizing its unique approach, ZL-1102 is being developed as a topical treatment for mild-to-moderate CPP, differentiating it from other anti-IL-17 products that target moderate-to-severe forms of the disease through systemic administration.
“ZL-1102 is the first IL-17 targeted topical treatment in development for patients with less severe forms of CPP.
In this 5-arm trial, approximately 250 patients will receive topical therapy for 16 weeks.

HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions

Retrieved on:

星期二, 五月 21, 2024

Oncology, Health, Diabetes, Research, Science, Pharmaceutical, Biotechnology, LNP, Duration, American Diabetes Association, EDT, Cancer, Injection, Clinical, Weight loss, Pharmaceutical industry

The abstract also will be published on the website of the ADA’s journal Diabetes.

Key Points:

The abstract also will be published on the website of the ADA’s journal Diabetes.
We believe HFG1 will require far fewer injections than existing GLP-1 products while providing steady-state agonist activity.”
Preliminary Study of Efficacy and Duration of an mRNA-Based GLP-1R Agonist in Diabetic Monkeys.
(Poster presentation number 1860-LB in category 12-B Clinical Therapeutics-Incretin-Based Therapies).
Saturday, June 22, 2024, 12:30 pm – 1:30 pm EDT (The poster will be displayed Saturday, Sunday and Monday in the Poster Hall; and at a Networking Reception Friday evening.)

Parallel Bio Launches Clinical Trial in a Dish to Speed Drug Discovery

Retrieved on:

星期四, 五月 16, 2024

Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies using human models at the earliest stages of drug discovery.

Key Points:

Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies using human models at the earliest stages of drug discovery.
Clinical Trial in a Dish creates human models using immune organoids scaled with robotics to represent the biology and diversity of a population.
Clinical Trial in a Dish is Parallel Bio’s first commercially available application of its immune system platform, which utilizes lymph-node organoids at scale to replicate the human immune system across diverse populations.
Parallel Bio is actively signing on additional pharmaceutical partners for Clinical Trial in a Dish.

Zoovu Addresses Massive Gap in Ecommerce Accessibility by Enabling Brands to Easily Create Accessible Shopping Experiences at Scale

Retrieved on:

星期四, 五月 16, 2024

Today, 27 percent of the population in the United States have accessibility challenges, according to the Center for Disease Control ( CDC ).

Key Points:

Today, 27 percent of the population in the United States have accessibility challenges, according to the Center for Disease Control ( CDC ).
Yet, more than 45% of major ecommerce sites fail to comply with ADA requirements and 96.3% had a detectable WCAG failure, according to the Bureau of Internet Accessibility’s 2023 State of Ecommerce Accessibility .
“When you consider that more of our lives are digital, it’s clear that ensuring accessibility is more than following the law.
Zoovu is known for managing massive and complex collections of product information, frequently changing content and product pages, chat assistant dialogs, and complex ecommerce functionality.

AdaCore Showcase Secure Avionics by Design at CYBERUK

Retrieved on:

星期一, 五月 13, 2024

View the full release here: https://www.businesswire.com/news/home/20240513452617/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240513452617/en/
AdaCore Showcase Secure Avionics by Design at CYBERUK (Photo: AdaCore UK)
AdaCore's SAbD technology has emerged from phase 1 of the collaborative and ongoing Edge Avionics programme.
Edge Avionics aims to research state-of-the-art systems security by building a real-world demonstrator avionics defense platform (hardware and software) that showcases cyber and battlefield resilience.
The Edge Avionics programme is funded by the Rapid Capabilities Office (RCO) of the UK Royal Air Force (UK RAF).
A CHERI compute solution provides one of the foundation elements for a secure by design system and is being explored through the Edge Avionics technical demonstrator.

New Synchrony Study Reveals Consumers May Not Recognize Hearing Loss Symptoms and Potential for Treatment

Retrieved on:

星期二, 五月 14, 2024

STAMFORD, Conn., May 14, 2024 /PRNewswire/ -- Hearing is a priority health concern for the majority of consumers, yet few take action to proactively manage their hearing health, according to a new study from Synchrony, a premier consumer financial services company, conducted on behalf of the company's leading healthcare financial solution, CareCredit. Synchrony's "Hearing Health & Loss Prevention" study surveyed more than 2,000 consumers between the ages of 18 and 55, as well as 26 audiologists about their perceptions and behaviors regarding hearing loss, associated care and devices.

Key Points:

Synchrony's "Hearing Health & Loss Prevention" study surveyed more than 2,000 consumers between the ages of 18 and 55, as well as 26 audiologists about their perceptions and behaviors regarding hearing loss, associated care and devices.
According to the survey, 70% of consumers consider their hearing a priority, yet less than 10% have visited an audiologist in the past year.
Overall, these results indicate that addressing hearing loss with hearing devices provides noticeable improvements, including greater participation in conversations and hobbies.
The Synchrony "Hearing Health & Loss Prevention" study was performed by Savanta and GCI Health on behalf of Synchrony.